- Home
- BXC vs DSGN Comparison
BXC vs DSGN Comparison
Compare BXC & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BXC | DSGN |
|---|---|---|
| Founded | 2004 | 2017 |
| Country | United States | United States |
| Employees | 1700 | N/A |
| Industry | Wholesale Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 587.2M | 579.9M |
| IPO Year | 2004 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BXC | DSGN |
|---|---|---|
| Price | $51.80 | $10.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $86.00 | $15.25 |
| AVG Volume (30 Days) | 84.6K | ★ 243.7K |
| Earning Date | 04-28-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.04 | N/A |
| Revenue Next Year | $5.09 | N/A |
| P/E Ratio | $2,261.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $44.78 | $2.62 |
| 52 Week High | $88.30 | $11.23 |
Technical Indicators
Market Signals| Indicator | BXC | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 37.32 | 51.24 |
| Support Level | N/A | $9.64 |
| Resistance Level | $74.08 | $11.18 |
| Average True Range (ATR) | 2.79 | 0.58 |
| MACD | -0.32 | -0.02 |
| Stochastic Oscillator | 34.42 | 42.86 |
Price Performance
Historical ComparisonAbout BXC Bluelinx Holdings Inc.
BlueLinx Holdings Inc is engaged in the wholesale distribution of residential and commercial building products. Its business products are split into two categories: Structural products include items such as lumber, plywood, oriented strand board, rebar, and remesh and Specialty products include items such as engineered wood, siding, millwork, outdoor living, specialty lumber and panels, and industrial products. The company's operations are carried out throughout the United States.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.